Search results for "Estrogen replacement"

showing 10 items of 43 documents

Decreased bioavailability of nitric oxide in aorta from ovariectomized senescent mice. Role of cyclooxygenase.

2015

This study investigates the effects of aging and/or ovariectomy on vascular reactivity to thromboxane A2 (TXA2) receptor stimulation with U46619, and the modulation by nitric oxide (NO) and cyclooxygenase (COX) in aorta from female senescence-accelerated mice (SAMP8) and from senescence resistant mice (SAMR1). Five-month-old female SAMR1 and SAMP8 were divided into three groups: sham-operated, ovariectomized and ovariectomized plus estradiol. Twenty-eight days after surgery, thoracic aortic rings were mounted for isometric recording of tension and concentration-response curves for U46619 (10(-10)-3 × 10(-7) M) were performed in the absence and in the presence of the NO synthase inhibitor N(…

0301 basic medicineAgingReceptors ThromboxaneAorta Thoracic030204 cardiovascular system & hematologyBiochemistrychemistry.chemical_compoundThromboxane A2Mice0302 clinical medicineEndocrinologySuperoxidesThoracic aortaVasoconstrictor AgentsbiologyEstradiolSuperoxideEstrogen Replacement TherapyAge FactorsOvariectomized ratFemaleMenopauseSignal Transductionmedicine.medical_specialtymedicine.drug_classOvariectomyDown-RegulationNitric OxideNitric oxide03 medical and health sciencesThromboxane A2medicine.arteryInternal medicineGeneticsmedicineAnimalsCyclooxygenase InhibitorsMolecular BiologyAortaDose-Response Relationship Drugbusiness.industryCell BiologyEnzyme ActivationOxidative Stress030104 developmental biologyEndocrinologychemistryEstrogenProstaglandin-Endoperoxide SynthasesVasoconstrictionbiology.proteinCyclooxygenaseNitric Oxide SynthasebusinessExperimental gerontology
researchProduct

Aging and serum exomiR content in women-effects of estrogenic hormone replacement therapy.

2017

AbstractExosomes participate in intercellular messaging by transporting bioactive lipid-, protein- and RNA-molecules and -complexes. The contents of the exosomes reflect the physiological status of an individual making exosomes promising targets for biomarker analyses. In the present study we extracted exosome microRNAs (exomiRs) from serum samples of premenopausal women (n = 8) and monozygotic postmenopausal twins (n = 10 female pairs), discordant for the use of estrogenic hormone replacement therapy (HRT), in order to see whether the age or/and the use of HRT associates with exomiR content. A total of 241 exomiRs were detected by next generation sequencing, 10 showing age, 14 HRT and 10 a…

0301 basic medicineMICRORNASTranscriptomeMedicineGene Regulatory NetworksMultidisciplinaryEstradiolmicroRNAEstrogen Replacement TherapyEndocrine system and metabolic diseasesHigh-Throughput Nucleotide Sequencingta3141Middle AgedMenopausePostmenopauseDISCORDANTPOSTMENOPAUSAL WOMENTransgender hormone therapymiRNAsBiomarker (medicine)SKELETAL-MUSCLEFemaleAdultEXPRESSIONmedicine.medical_specialtyMENOPAUSEBODY-COMPOSITIONexosomesta3111ExosomeArticleestrogenic hormone replacement therapy03 medical and health sciencesBreast cancerInternal medicineHumansBREAST-CANCERbusiness.industryta1184Gene Expression ProfilingReproducibility of Resultsbiomarkersmedicine.diseaseGene expression profilingMONOZYGOTIC TWIN PAIRS030104 developmental biologyEndocrinologyPremenopauseCELLSNext-generation sequencing3111 Biomedicinemikro-RNAbusinessTranscriptomeHormone
researchProduct

Leukocyte and Skeletal Muscle Telomere Length and Body Composition in Monozygotic Twin Pairs Discordant for Long-term Hormone Replacement Therapy

2017

Estrogen-based hormone replacement therapy (HRT) may be associated with deceleration of cellular aging. We investigated whether long-term HRT has effects on leukocyte (LTL) or mean and minimum skeletal muscle telomere length (SMTL) in a design that controls for genotype and childhood environment. Associations between telomeres, body composition, and physical performance were also examined. Eleven monozygotic twin pairs (age 57.6 ± 1.8 years) discordant for HRT were studied. Mean duration of HRT use was 7.3 ± 3.7 years in the user sister, while their co-twins had never used HRT. LTL was measured by qPCR and SMTLs by southern blot. Body and muscle composition were estimated by bioimpedance an…

0301 basic medicinemedicine.medical_specialtymedicine.drug_classMonozygotic twinmedicine.disease_cause03 medical and health sciencesGrip strengthJumpingInsulin resistanceInternal medicinebioimpedancemedicineElectric ImpedanceLeukocytesestrogenHumanstietokonetomografiapost-menopausalMuscle SkeletalExerciseGenetics (clinical)Hand Strengthbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologySkeletal muscleta3141computed tomographyTwins MonozygoticMiddle AgedTelomeremedicine.diseasetelomeresObesitypercentage of fatfat-free mass030104 developmental biologyEndocrinologymedicine.anatomical_structuretwin designEstrogenTransgender hormone therapyPediatrics Perinatology and Child HealthBody CompositionFemaletelomeeritbusinessTwin Research and Human Genetics
researchProduct

Hormone therapy is associated with better body composition and adipokine/glucose profiles

2012

Objective: The aim of this study was to evaluate the possibility of preventing the metabolic health consequences of postmenopausal hypogonadism with the use of long-term hormone therapy (HT). Methods: We used a monozygotic co-twin control design including 10 twin pairs (aged 56-62 y) discordant for HT (duration of HT, 2-10 y). In addition, 14 premenopausal women (aged 29-35 y) who did not use HT were studied to evaluate the differences in metabolic health between the premenopausal and postmenopausal states. Body composition was determined, and waist-to-hip ratio was used as an estimate for fat distribution. Serum sex steroids, sex hormone-binding globulin, and serum lipid and glucose profil…

AdultBlood Glucosenaisetmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentkehon koostumusCo twin controlAdipose tissueAdipokineCarbohydrate metabolismAdipokinesSex Hormone-Binding GlobulinInternal medicineLeukocytesmedicineHumansRNA MessengerGonadal Steroid HormonesMuscle SkeletalChemokine CCL2kehonkoostumusMetabolic healthkaksostutkimusWaist-Hip Ratiobusiness.industryEstrogen Replacement TherapyadipokoinesObstetrics and Gynecologyta3141Twin studyTwins MonozygoticMiddle Agedadipokiinitmedicine.diseaseLipidsPostmenopauseMenopauseEndocrinologyAdipose TissuePremenopauseEstrogenCase-Control StudiesBody CompositionFemaleHormone therapyInsulin ResistancebusinessMenopause
researchProduct

Physiological Estrogen Replacement May Enhance the Effectiveness of the Gonadotropin-Releasing Hormone Agonist in the Treatment of Hirsutism

1994

GnRH agonists (GnRH-A) have been used for the treatment of hirsutism in women with ovarian hyperandrogenism. However, significant side-effects, including vasomotor symptoms and bone loss, have prevented the long term use of this therapy. In this study, we evaluated the effects of low dose (physiological) estrogen replacement on the side-effects and clinical and hormonal parameters of 22 hirsute women with ovarian hyperandrogenism when treated with a long-acting GnRH-A, Decapeptyl. Ten patients with Ferriman-Gallwey (FG) scores averaging 13.4 +/- 1.5 were randomly assigned to be treated with Decapeptyl alone (3.75 mg, im, every 28 days for 6 months), and 12 other patients with FG scores aver…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryMedroxyprogesterone AcetateGonadotropin-releasing hormoneBiochemistryGonadotropin-Releasing HormoneEndocrinologyGonadotropin-releasing hormone agonistInternal medicinemedicineHumansMedroxyprogesterone acetateEstrogen replacementConjugated Equine EstrogensTestosteronehirsutismTriptorelin PamoateVasomotorbusiness.industryEstrogen Replacement TherapyBiochemistry (medical)HyperandrogenismObstetrics and GynecologyDrug SynergismGeneral Medicinemedicine.diseaseMenstruationmedicine.anatomical_structureEndocrinologyEstrogenGonadotropins PituitaryAndrogensDrug Therapy CombinationFemalebusinesshormones hormone substitutes and hormone antagonistsHormonemedicine.drugObstetrical & Gynecological Survey
researchProduct

Effect of continuous oestradiol-medroxyprogesterone administration on plasma lipids and lipoproteins

1991

Plasma lipids and lipoproteins were measured in 21 post-menopausal women after 4 and 8 months of continuous treatment with an orally administered combination of oestradiol and medroxyprogesterone acetate. The mean concentrations of cholesterol and low-density-lipoprotein (LDL) cholesterol were reduced by 12% (P less than 0.001) and 11% (P less than 0.01), respectively, after 4 months of treatment and by 9% (P less than 0.05) and 12% (P less than 0.05) after 8 months. The mean level of high-density-lipoprotein (HDL) cholesterol showed an initial fall of 5% (P less than 0.05) after 4 months and then increased by 13% (P less than 0.05) after 8 months of treatment. The plasma triglycerides leve…

AdultMedroxyprogesteronemedicine.medical_specialtymedicine.drug_classLipoproteinsMedroxyprogesteronemedicine.medical_treatmentGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundInternal medicinePlasma lipidsHumansMedicineMedroxyprogesterone acetateClinical significanceProspective StudiesEstradiolProgestogenbusiness.industryCholesterolEstrogen Replacement TherapyObstetrics and GynecologyMiddle AgedLipidsEndocrinologychemistryEstrogenDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Menopausebusinessmedicine.drugLipoproteinMaturitas
researchProduct

Evaluation of the antiproliferative, proapoptotic, and antiangiogenic effects of a double-stranded RNA mimic complexed with polycations in an experim…

2015

Objective To assess the antiproliferative, proapoptotic, and antiangiogenic effects of the double-stranded RNA mimic polyinosine-polycytidylic acid (pIC) complexed with polyethylenimine [pIC PEI ] in xenografted human leiomyomas. Design Heterologous leiomyoma mouse model. Setting University-affiliated infertility center. Animal(s) Ovariectomized and hormone-replaced nude mice (n = 16) who received human leiomyoma fragment transplantation. Intervention(s) Leiomyoma fragments placed in the peritoneum of 5-week-old nude female mice and treated with the vehicle (n = 8) or 0.6 mg/kg [pIC PEI ] (n = 8) for 4 weeks. Main Outcome Measure(s) The size of the leiomyoma implants, and cellular prolifera…

AdultTime FactorsAngiogenesisOvariectomyHeterologousMice NudeAngiogenesis InhibitorsApoptosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePeritoneummedicineTumor Cells CulturedAnimalsHumansPolyethyleneimineCell ProliferationPolyethylenimine030219 obstetrics & reproductive medicineLeiomyomaNeovascularization PathologicCell growthbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysTumor BurdenTransplantationPlatelet Endothelial Cell Adhesion Molecule-1Disease Models AnimalLeiomyomamedicine.anatomical_structureKi-67 AntigenPoly I-CReproductive MedicinechemistryApoptosis030220 oncology & carcinogenesisImmunologyUterine NeoplasmsCancer researchFemalebusinessFertility and sterility
researchProduct

Effect of oestrogen/gestagen replacement therapy on liver enzymes in patients with Ullrich-Turner syndrome.

1995

The absence of breast development and the prevention of osteoporosis in Ullrich-Turner syndrome (UTS) require oestrogen/gestagen substitution therapy. In 8 out of 35 (23%) patients with UTS treated with conjugated equine oestrogens and cyclically with norethisterone acetate, the serum liver enzymes increased to conspicuous levels (AST 35; 20-73 U/l, ALT 92; 37-141 U/l, GGT 77; 25-227 U/l, [median; min-max]). These findings were compared with those in 41 tall girls who received a six-fold larger dose of conjugated equine oestrogens for the reduction of final height. None of these 41 girls showed abnormal serum liver enzyme levels. The conspicuous rise in serum liver enzyme levels occurred in…

Adultmedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentOsteoporosisTurner SyndromeLiver Function TestsInternal medicineTurner syndromeBiopsymedicineHumansAspartate AminotransferasesSexual MaturationChildChemotherapyEstrogens Conjugated (USP)medicine.diagnostic_testbusiness.industryEstrogen Replacement TherapyAlanine Transaminasegamma-Glutamyltransferasemedicine.diseaseNorethisterone acetateBody HeightNorethindrone AcetateEndocrinologyEstrogenPediatrics Perinatology and Child HealthToxicityFemaleNorethindroneLiver function testsbusinessmedicine.drugFollow-Up StudiesEuropean journal of pediatrics
researchProduct

Characteristics of urinary luteinizing hormone (LH) during the induction of LH surges of different magnitude in blood

1995

Urinary luteinizing hormone (LH) testing has been proposed as a reliable method for the prediction of ovulation but its accuracy has been challenged by some studies. To check how accurately the oscillations of urinary LH reflected the plasma changes, surges of LH of different magnitude and duration were artificially induced in plasma and the hormone was measured simultaneously in urine. Post-menopausal women (n = 16) were stimulated during 1 week with a combination of transdermal oestradiol (400 micrograms) and i.m. progesterone (25 mg on day 4, 50 mg on day 5) to obtain an LH discharge comparable with the pre-ovulatory LH peak. A short and moderate peak of LH was induced by the i.v. inject…

Adultmedicine.medical_specialtyTime Factorsmedicine.drug_classmedia_common.quotation_subjectRadioimmunoassayGonadotropin-releasing hormoneUrineBuserelinSensitivity and SpecificityGonadotropin-Releasing HormoneAndrologyInternal medicinemedicineHumansOvulationProgesteronemedia_commonOvulation DetectionEstradiolChemistryEstrogen Replacement TherapyRehabilitationReproducibility of ResultsObstetrics and GynecologyLuteinizing HormoneMiddle Agedmedicine.diseaseBuserelinMenopauseEndocrinologyReproductive MedicineFemaleMenopauseGonadotropinLuteinizing hormonemedicine.drugHormoneHuman Reproduction
researchProduct

The effect of hormonal status on the expression of estrogen and progesterone receptor in vaginal wall and periurethral tissue in urogynecological pat…

2009

Abstract Objective Our objective was to study the expression of estrogen receptor (ER) isoforms ER alpha (α) and ER beta (β) and of progesterone receptor (PR) in the vaginal wall and in periurethral tissue of women who underwent urogynecological surgical treatment with reference to estrogen status. Study design The study included 89 patients undergoing vaginal surgery for urogynecological conditions. Patients’ history and clinical data including estrogen status and body mass index (BMI) were evaluated. Biopsies from the vaginal wall and from periurethral tissue were obtained during surgery. The expression of ER α and β and of PR in vaginal wall and periurethral tissue was measured by RT-PCR…

Adultmedicine.medical_specialtymedicine.drug_classReceptor expressionEstrogen receptorUrethraInternal medicineProgesterone receptormedicineHumansEstrogen receptor betaAgedAged 80 and overReverse Transcriptase Polymerase Chain Reactionbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyEstrogensMiddle AgedEndocrinologymedicine.anatomical_structureReceptors EstrogenReproductive MedicineEstrogenVaginaVaginaFemaleReceptors ProgesteronebusinessProgestinEstrogen receptor alphaEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct